You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

platinum sensitive peritoneal cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

Active, not recruiting
  • Relapsed Ovarian Cancer
  • +2 more
  • Olaparib 300mg tablets
  • Beijing, China
  • +24 more
Dec 5, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Oklahoma City (Paclitaxel, Cisplatin IP)

Terminated
Has Results
  • Ovarian Cancer
  • +3 more
  • Paclitaxel, Cisplatin IP
  • Oklahoma City, Oklahoma
    University of Oklahoma Health Sciences Center
Apr 28, 2021

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Platinum-sensitive Relapsed Ovarian Cancer Trial in China (ZL-2306(nirapairb), Placebos)

Active, not recruiting
  • Platinum-sensitive Relapsed Ovarian Cancer
  • Guangzhou, Guangdong, China
  • +26 more
Oct 14, 2021

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
Has Results
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRĪ± peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Germany, Italy (Niraparib)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Berlin, Germany
  • +11 more
Sep 15, 2021

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial in Worldwide (Oral rucaparib)

Completed
Has Results
  • Ovarian Cancer
  • +3 more
  • Oral rucaparib
  • Anchorage, Alaska
  • +74 more
Jan 31, 2022

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Metastatic Breast Cancer Trial in Shanghai (Vinorelbine, DDP)

Recruiting
  • Metastatic Breast Cancer
  • Shanghai, China
    Fudan University Cancer Hospital
Apr 19, 2022

Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

Recruiting
  • Recurrent Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • Simvastatin 40mg
  • Los Angeles, California
    Cedars Sinai Medical Center
Apr 21, 2022

Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,

Recruiting
  • Hormone Sensitive Metastatic Prostate Cancer
  • +3 more
  • Nanjing, Jiangsu, China
    Department of Urology, Drum Tower Hospital, Medical School of Na
Jul 13, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-Sensitive Biliary Tract Cancer Trial (Cisplatin, Gemcitabine, Oxaliplatin)

Withdrawn
  • Platinum-Sensitive Biliary Tract Cancer
  • (no location specified)
May 27, 2022

Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Fuzuloparib Combination with Bevacizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Cente
Apr 14, 2023

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,

Recruiting
  • Ovarian Cancer by FIGO Stage
  • +2 more
  • Oregovomab
  • +3 more
  • Daegu, Korea, Republic of
  • +5 more
Oct 20, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022